Degenerative disease

Pacific Dental Services Recognizes American Heart Month by Highlighting Link Between Oral Health and Heart Health

Retrieved on: 
Thursday, February 9, 2023
Health, Diabetes, Research, Smile, Stroke, Mouth, CPR, Cardiovascular disease, Sneeze, Smoking, Risk factor, Lung, Degenerative disease, Cancer, American Heart, Risk, Pregnancy, Periodontology, American Heart Association, Patient, American Heart Month, Obesity, Skin, Movement, Dentistry, Periodontal disease, Dementia, Orange County Fire, Dental Service Organizations, National Heart, Lung, and Blood Institute, Organization, National Heart Foundation of Australia, Death, Orange County Fire Authority, PDS, Pain, Inflammation, Pharmaceutical industry, Woman

Irvine, California, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Pacific Dental Services® (PDS), one of the nation’s leading dental support organizations, is recognizing American Heart Month by continuing to raise awareness of the link between oral health and heart health with several campaigns targeted toward patients and its own team members.

Key Points: 
  • Irvine, California, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Pacific Dental Services® (PDS), one of the nation’s leading dental support organizations, is recognizing American Heart Month by continuing to raise awareness of the link between oral health and heart health with several campaigns targeted toward patients and its own team members.
  • Heart disease is the leading cause of death in the United States, according to the American Heart Association .
  • While oral health likely doesn’t play a role in all of those events, the association between oral health and heart health is too strong to ignore.
  • “Pacific Dental Services continues to lead the way in highlighting the connection between oral health and overall health, or what we call the Mouth-Body Connection®, and the benefits that are possible through dental-medical integration,” said Stephen E. Thorne IV, Founder and CEO, Pacific Dental Services.

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, February 9, 2023
Annual general meeting, Research, Society, Food, ASH, Safety, Phase 1, Lymphoma, United Kingdom, Lymphatic system, IND, Memorial Sloan Kettering Cancer Center, Cancer, Society for Immunotherapy of Cancer, Chronic lymphocytic leukemia, CLL, Gilead Sciences, Immunotherapy, Calendar, Gilead, Lymphoid leukemia, BTK, Patient, SAN, Information technology, Clinical trial, FDA, SKI, Investment, SITC, MSCE, Collaboration, Degenerative disease, Therapy, Pharmaceutical industry, Vaccine, Sanofi

SAN FRANCISCO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fourth quarter and fiscal year ended November 30, 2022 and provided a corporate update.

Key Points: 
  • SAN FRANCISCO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fourth quarter and fiscal year ended November 30, 2022 and provided a corporate update.
  • “In 2022, Nurix achieved multiple ‘firsts’ in oncology with our drug candidates, establishing Nurix as the leader in the targeted protein modulation field,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix.
  • Throughout 2022, Nurix made significant progress within its collaborations as evidenced by the receipt of multiple milestone payments from both partners.
  • Cash, cash equivalents and marketable securities was $373.0 million as of November 30, 2022, compared with $432.9 million as of November 30, 2021.

Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)

Retrieved on: 
Thursday, February 9, 2023
DM1, Vertex, Hart–Scott–Rodino Antitrust Improvements Act, Duchenne muscular dystrophy, Degenerative disease, Entrada, HSR, Patient, Research, Therapy, EEV, Pharmaceutical industry

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and closing of the Company’s previously announced strategic collaboration and license agreement with Vertex.

Key Points: 
  • Under the terms of the agreement announced on December 8, 2022, Entrada will receive an upfront payment of $224 million, as well as an equity investment of $26 million at $16.26 per share.
  • Entrada is eligible to receive up to $485 million for the successful achievement of certain research, development, regulatory and commercial milestones, and tiered royalties on future net sales for any products that may result from this collaboration agreement.
  • The agreement includes a four-year global research collaboration whereby Entrada will continue to advance and receive payments for certain research activities related to ENTR-701, as well as additional DM1-related research activities.
  • Vertex will be responsible for global development, manufacturing and commercialization of ENTR-701 and any additional programs stemming from Entrada’s DM1 research efforts.

NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders

Retrieved on: 
Thursday, February 9, 2023
Neurodegeneration, WEHI, Medicine, Mitochondrial permeability transition pore, Degenerative disease, IND, R, Neuroinflammation, MOA, CSO, Survival, Therapy, Drug development, NRG, Drug discovery, Mitochondrion, MND, Sclerosis (medicine), ALS, MPTP, SBC, École Polytechnique, Cell, AstraZeneca, Pharmaceutical industry, Fine chemical, Galderma, Chemistry, Evotec

Dr Ouvry brings 20 years of international medicinal chemistry experience gained at Evotec, Galderma, AstraZeneca and SCYNEXIS.

Key Points: 
  • Dr Ouvry brings 20 years of international medicinal chemistry experience gained at Evotec, Galderma, AstraZeneca and SCYNEXIS.
  • NRG Therapeutics’ co-founder and CEO Dr Neil Miller said, “We are expanding following our £16m series A financing and I am delighted to welcome Gilles to our team.
  • There is now a substantial body of evidence demonstrating mitochondrial failure or dysfunction is common across many degenerative diseases.
  • Gilles Ouvry Ph.D., VP of Chemistry at NRG Therapeutics said, “I have been impressed by the potential of NRG’s small molecules and am excited to be working with the team to move the programs forward.

Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock

Retrieved on: 
Wednesday, February 8, 2023
ThinkEquity, Security (finance), Cancer, Sale, Graves' ophthalmopathy, Patient, TED, Toxicity, Degenerative disease, Therapy, Pharmaceutical industry

New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (the “Company” or “Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced that it has closed a private placement, which resulted in gross proceeds to Lirum of over $7 million, before deducting offering expenses.

Key Points: 
  • New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (the “Company” or “Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced that it has closed a private placement, which resulted in gross proceeds to Lirum of over $7 million, before deducting offering expenses.
  • Net proceeds will be used by Lirum primarily to advance its clinical and preclinical studies, for working capital, and to potentially expand its product candidate pipeline.
  • Lirum’s lead product candidate, LX-101, is a novel, clinical-stage, targeted therapy directed to the IGF-1 receptor (IGF-1R).
  • No dose limiting toxicity or maximum tolerated dose have been reached, and Lirum intends to continue to dose escalate and optimize the administration schedule.

Disc Medicine to Participate in SVB Securities Global Biopharma Conference

Retrieved on: 
Wednesday, February 8, 2023
Conference, Patient, IRON, Degenerative disease, Pharmaceutical industry, Self storage

WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat in a virtual format at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 8:40 a.m.

Key Points: 
  • WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat in a virtual format at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 8:40 a.m.
  • ET.
  • A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available.

Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024

Retrieved on: 
Wednesday, February 8, 2023
MSD, Pathogen, MBA, CHB, National Institute of Allergy and Infectious Diseases, Infection, COVID-19, Plasma protein binding, Metropolitan, Rega Institute for Medical Research, GLP, Sirna, Therapy, NASH, Jacob Aligo, NIH, Leuven Centre for Global Governance Studies, NIAID, Patient, Fatty liver disease, SAN, Merck, Merck & Co., Degenerative disease, SAD, Liver disease, Workforce, Drug design, Doctor of Philosophy, Discovery, Research, KU Leuven, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced a portfolio reprioritization. Aligos’ highest priorities will be focused on rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs as well as maintaining its ongoing NASH oligonucleotide research collaborations with Merck & Co. (MSD outside the U.S. and Canada). Additionally, the Company plans to complete the ≤48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations.

Key Points: 
  • As a result of the portfolio reprioritization, realignment of its workforce, and other cost-saving measures, the Company expects to maintain a strong balance sheet and extend its projected cash runway to the end of 2024.
  • “I would like to express my sincere gratitude to the employees who are being affected by this reprioritization.
  • ALG-055009 – the Company’s THR-β agonist in development for NASH is expected to complete an ongoing Phase 1 study in H1 2023.
  • Aligos plans to continue to support its collaboration agreements, including the agreement with Merck & Co. to develop oligonucleotide candidates to address NASH.

iSpecimen Expands Biospecimen Provider Network

Retrieved on: 
Wednesday, February 8, 2023
Diabetes, Chronic obstructive pulmonary disease, Degenerative disease, Blood, OB/GYN, Infection, Patient, Clinical trial, Asthma, COPD, Growth, Hypertension, Research, Pharmaceutical industry

LEXINGTON, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that over the course of the second half of 2022, the Company added and onboarded seven new biospecimen providers to the iSpecimen Marketplace®, for both banked and prospectively collected specimens.

Key Points: 
  • LEXINGTON, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that over the course of the second half of 2022, the Company added and onboarded seven new biospecimen providers to the iSpecimen Marketplace®, for both banked and prospectively collected specimens.
  • As part of this network expansion, researchers utilizing the iSpecimen Marketplace® will have access to samples of larger patient populations with diverse phenotypes across the U.S. and Europe.
  • “By tracking and monitoring demand and trends of incoming researcher requests, iSpecimen is able to strategically determine the biggest gaps in specimen procurement and effectively expand our network,” said Tracy Curley, CEO of iSpecimen.
  • The iSpecimen Marketplace continues to function as a powerful, innovative biospecimen matchmaking platform that researchers and suppliers alike can utilize worldwide to obtain the samples they need to advance essential research.

Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023

Retrieved on: 
Wednesday, February 8, 2023
Degenerative disease, Pharmaceutical industry

REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Wednesday, February 22, 2023.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Wednesday, February 22, 2023.
  • Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m.
  • ET.

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 7, 2023
Conference, Degenerative disease, SAN, Therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference and Cowen’s 43rd Annual Health Care Conference.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference and Cowen’s 43rd Annual Health Care Conference.
  • Details of participation are as follows: